Business Context and Reporting Period
This Form 8-K was filed by Supernus Pharmaceuticals, Inc. on May 20, 2021, reporting events occurring on that date. The filing details the entry into a Commercial Supply Agreement with Catalent Pharma Solutions, LLC, effective May 12, 2021. This agreement supports the commercial launch of Qelbree (viloxazine HCL extended release capsules), which received FDA approval on April 2, 2021, and launched on May 24, 2021.
Key Financial Metrics
This filing is a Current Report (Form 8-K) and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the terms of a material definitive agreement.
Material Changes and Agreement Terms
- Agreement Counterparty: Catalent Pharma Solutions, LLC.
- Scope: Catalent will manufacture commercial quantities of Qelbree worldwide (excluding sanctioned countries) at its facility.
- Responsibilities: Supernus provides the Active Pharmaceutical Ingredient (API) and other materials at no cost to Catalent. Catalent procures raw materials, supplies, and packaging for compounding, filling, encapsulating, and bulk packaging.
- Term: The agreement runs until December 31, 2026, with automatic two-year extensions unless terminated by notice.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future performance, or specific risk factors beyond the standard exclusion of countries under comprehensive sanctions. The agreement is intended to be filed as an exhibit to the Quarterly Report on Form 10-Q for the period ended June 30, 2021.
Investor Verification Checklist
- Verify the full text of the Commercial Supply Agreement when filed as an exhibit to the Q2 2021 Form 10-Q.
- Confirm the commercial launch status and initial sales performance of Qelbree in subsequent earnings reports.
- Monitor for any future amendments to the manufacturing agreement or changes in supply chain responsibilities.